A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Feb 23, 2024 - P2 | N=41 | Completed | Sponsor: Endeavor Biomedicines, Inc. | Active, not recruiting ➔ Completed
Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|